{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:08:37Z","timestamp":1771006117811,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Ministry of Education, Science, and Culture, Japan","award":["16H05416"],"award-info":[{"award-number":["16H05416"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["19H03731"],"award-info":[{"award-number":["19H03731"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["25293323"],"award-info":[{"award-number":["25293323"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["16K10862"],"award-info":[{"award-number":["16K10862"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["15K10446"],"award-info":[{"award-number":["15K10446"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["18K15242"],"award-info":[{"award-number":["18K15242"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["16K10596"],"award-info":[{"award-number":["16K10596"]}]},{"name":"The Ministry of Education, Science, and Culture, Japan","award":["19K16835"],"award-info":[{"award-number":["19K16835"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00262-020-02774-7","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T05:10:28Z","timestamp":1604553028000},"page":"1405-1417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma"],"prefix":"10.1007","volume":"70","author":[{"given":"Yusuke","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1050","authenticated-orcid":false,"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Demiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Komatsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Sugiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hasei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2774_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776\u2013790. https:\/\/doi.org\/10.1200\/JCO.2002.20.3.776","journal-title":"J Clin Oncol"},{"key":"2774_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/cncr.21724","volume":"106","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154\u20131161. https:\/\/doi.org\/10.1002\/cncr.21724","journal-title":"Cancer"},{"key":"2774_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00776-009-1347-6","volume":"14","author":"Y Iwamoto","year":"2009","unstructured":"Iwamoto Y, Tanaka K, Isu K et al (2009) Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14:397\u2013404. https:\/\/doi.org\/10.1007\/s00776-009-1347-6","journal-title":"J Orthop Sci"},{"key":"2774_CR4","doi-asserted-by":"publisher","first-page":"704872","DOI":"10.1155\/2012\/704872","volume":"2012","author":"DC Allison","year":"2012","unstructured":"Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012:704872. https:\/\/doi.org\/10.1155\/2012\/704872","journal-title":"Sarcoma"},{"key":"2774_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","volume":"20","author":"AM Goorin","year":"2002","unstructured":"Goorin AM, Harris MB, Bernstein M et al (2002) Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426\u2013433. https:\/\/doi.org\/10.1200\/JCO.2002.20.2.426","journal-title":"J Clin Oncol"},{"key":"2774_CR6","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1200\/JCO.2002.11.028","volume":"20","author":"H Tsuchiya","year":"2002","unstructured":"Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K (2002) Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 20:3470\u20133477. https:\/\/doi.org\/10.1200\/JCO.2002.11.028","journal-title":"J Clin Oncol"},{"key":"2774_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fonc.2016.00022","volume":"6","author":"L Vasquez","year":"2016","unstructured":"Vasquez L, Tarrillo F, Oscanoa M, Maza I, Geronimo J, Paredes G, Silva JM, Sialer L (2016) Analysis of prognostic factors in high-grade osteosarcoma of the extremities in children: a 15-year single-institution experience. Front Oncol 6:22. https:\/\/doi.org\/10.3389\/fonc.2016.00022","journal-title":"Front Oncol"},{"key":"2774_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"2774_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"2774_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493\u20131501. https:\/\/doi.org\/10.1016\/S1470-2045(17)30624-1","journal-title":"Lancet Oncol"},{"key":"2774_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.ccr-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima T, Kagawa S, Kobayashi N et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285\u2013292. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1075-3","journal-title":"Clin Cancer Res"},{"key":"2774_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1349-7006.2007.00665.x","volume":"99","author":"Y Hashimoto","year":"2008","unstructured":"Hashimoto Y, Watanabe Y, Shirakiya Y et al (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 99:385\u2013390. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00665.x","journal-title":"Cancer Sci"},{"key":"2774_CR13","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-10-2066","volume":"17","author":"T Sasaki","year":"2011","unstructured":"Sasaki T, Tazawa H, Hasei J et al (2011) Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res 17:1828\u20131838. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2066","journal-title":"Clin Cancer Res"},{"key":"2774_CR14","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-10-2333","volume":"70","author":"S Kuroda","year":"2010","unstructured":"Kuroda S, Fujiwara T, Shirakawa Y et al (2010) Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 70:9339\u20139348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2333","journal-title":"Cancer Res"},{"key":"2774_CR15","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/1535-7163.MCT-08-0901","volume":"8","author":"D Liu","year":"2009","unstructured":"Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T (2009) Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 8:980\u2013987. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0901","journal-title":"Mol Cancer Ther"},{"key":"2774_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/mt.2009.262","volume":"18","author":"J Nemunaitis","year":"2010","unstructured":"Nemunaitis J, Tong AW, Nemunaitis M et al (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18:429\u2013434. https:\/\/doi.org\/10.1038\/mt.2009.262","journal-title":"Mol Ther"},{"key":"2774_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","volume":"15","author":"A Tesniere","year":"2008","unstructured":"Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15:3\u201312. https:\/\/doi.org\/10.1038\/sj.cdd.4402269","journal-title":"Cell Death Differ"},{"key":"2774_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51\u201372. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008","journal-title":"Annu Rev Immunol"},{"key":"2774_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071479","author":"H Tazawa","year":"2017","unstructured":"Tazawa H, Kuroda S, Hasei J, Kagawa S, Fujiwara T (2017) Impact of autophagy in oncolytic adenoviral therapy for cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18071479","journal-title":"Int J Mol Sci"},{"key":"2774_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/gt.2016.70","volume":"24","author":"E Ilett","year":"2017","unstructured":"Ilett E, Kottke T, Thompson J et al (2017) Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther 24:21\u201330. https:\/\/doi.org\/10.1038\/gt.2016.70","journal-title":"Gene Ther"},{"key":"2774_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642\u2013662. https:\/\/doi.org\/10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"key":"2774_CR22","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","volume":"77","author":"L Fend","year":"2017","unstructured":"Fend L, Yamazaki T, Remy C et al (2017) Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res 77:4146\u20134157. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2165","journal-title":"Cancer Res"},{"key":"2774_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/mt.2015.156","volume":"24","author":"K Rajani","year":"2016","unstructured":"Rajani K, Parrish C, Kottke T et al (2016) Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 24:166\u2013174. https:\/\/doi.org\/10.1038\/mt.2015.156","journal-title":"Mol Ther"},{"key":"2774_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/a:1006767007547","volume":"18","author":"C Khanna","year":"2000","unstructured":"Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L (2000) An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 18:261\u2013271. https:\/\/doi.org\/10.1023\/a:1006767007547","journal-title":"Clin Exp Metastasis"},{"key":"2774_CR25","first-page":"3750","volume":"61","author":"C Khanna","year":"2001","unstructured":"Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750\u20133759","journal-title":"Cancer Res"},{"key":"2774_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1349-7006.2001.tb01144.x","volume":"92","author":"T Kusumi","year":"2001","unstructured":"Kusumi T, Nishi T, Tanaka M, Tsuchida S, Kudo H (2001) A murine osteosarcoma cell line with a potential to develop ossification upon transplantation. Jpn J Cancer Res 92:649\u2013658. https:\/\/doi.org\/10.1111\/j.1349-7006.2001.tb01144.x","journal-title":"Jpn J Cancer Res"},{"key":"2774_CR27","first-page":"1627","volume":"28","author":"T Nishi","year":"2008","unstructured":"Nishi T, Kusumi T, Tanaka M, Sato F, Sasaki M, Kudo H, Kijima H (2008) Establishment of transplantable murine osteosarcoma cell line with endochondral ossification. Anticancer Res 28:1627\u20131631","journal-title":"Anticancer Res"},{"key":"2774_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320\u20131323. https:\/\/doi.org\/10.1126\/science.275.5304.1320","journal-title":"Science"},{"key":"2774_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-e","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309\u2013319. https:\/\/doi.org\/10.1016\/0092-8674(93)90231-e","journal-title":"Cell"},{"key":"2774_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1158\/1535-7163.MCT-12-0869","volume":"12","author":"J Hasei","year":"2013","unstructured":"Hasei J, Sasaki T, Tazawa H et al (2013) Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther 12:314\u2013325. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0869","journal-title":"Mol Cancer Ther"},{"key":"2774_CR31","doi-asserted-by":"publisher","first-page":"28953","DOI":"10.1038\/srep28953","volume":"6","author":"S Osaki","year":"2016","unstructured":"Osaki S, Tazawa H, Hasei J et al (2016) Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. Sci Rep 6:28953. https:\/\/doi.org\/10.1038\/srep28953","journal-title":"Sci Rep"},{"key":"2774_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-12-103","volume":"12","author":"DL Bartlett","year":"2013","unstructured":"Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103. https:\/\/doi.org\/10.1186\/1476-4598-12-103","journal-title":"Mol Cancer"},{"key":"2774_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fonc.2014.00074","volume":"4","author":"ZS Guo","year":"2014","unstructured":"Guo ZS, Liu Z, Bartlett DL (2014) Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 4:74. https:\/\/doi.org\/10.3389\/fonc.2014.00074","journal-title":"Front Oncol"},{"key":"2774_CR34","doi-asserted-by":"publisher","first-page":"e947872","DOI":"10.4161\/21624011.2014.947872","volume":"3","author":"H Jiang","year":"2014","unstructured":"Jiang H, Fueyo J (2014) Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology 3:e947872. https:\/\/doi.org\/10.4161\/21624011.2014.947872","journal-title":"Oncoimmunology"},{"key":"2774_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"2774_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","volume":"23","author":"K Kono","year":"2020","unstructured":"Kono K, Nakajima S, Mimura K (2020) Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer 23:565\u2013578. https:\/\/doi.org\/10.1007\/s10120-020-01090-4","journal-title":"Gastric Cancer"},{"key":"2774_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061324","author":"A Passardi","year":"2017","unstructured":"Passardi A, Canale M, Valgiusti M, Ulivi P (2017) Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18061324","journal-title":"Int J Mol Sci"},{"key":"2774_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1758834014567469","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Peng C, Sosman JA (2015) Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 7:97\u2013106. https:\/\/doi.org\/10.1177\/1758834014567469","journal-title":"Ther Adv Med Oncol"},{"key":"2774_CR39","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","volume":"334","author":"M Michaud","year":"2011","unstructured":"Michaud M, Martins I, Sukkurwala AQ et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334:1573\u20131577. https:\/\/doi.org\/10.1126\/science.1208347","journal-title":"Science"},{"key":"2774_CR40","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.jbo.2019.100235","volume":"16","author":"O Camuzard","year":"2019","unstructured":"Camuzard O, Santucci-Darmanin S, Carle GF, Pierrefite-Carle V (2019) Role of autophagy in osteosarcoma. J Bone Oncol 16:100235. https:\/\/doi.org\/10.1016\/j.jbo.2019.100235","journal-title":"J Bone Oncol"},{"key":"2774_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3389\/fonc.2019.01232","volume":"9","author":"J Niu","year":"2019","unstructured":"Niu J, Yan T, Guo W, Wang W, Zhao Z (2019) Insight into the role of autophagy in osteosarcoma and its therapeutic implication. Front Oncol 9:1232. https:\/\/doi.org\/10.3389\/fonc.2019.01232","journal-title":"Front Oncol"},{"key":"2774_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.18926\/AMO\/52006","volume":"67","author":"H Tazawa","year":"2013","unstructured":"Tazawa H, Kagawa S, Fujiwara T (2013) Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Acta Med Okayama 67:333\u2013342. https:\/\/doi.org\/10.18926\/AMO\/52006","journal-title":"Acta Med Okayama"},{"key":"2774_CR43","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/gt.2008.98","volume":"15","author":"T Yokoyama","year":"2008","unstructured":"Yokoyama T, Iwado E, Kondo Y et al (2008) Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15:1233\u20131239. https:\/\/doi.org\/10.1038\/gt.2008.98","journal-title":"Gene Ther"},{"key":"2774_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","volume":"14","author":"GE Blair","year":"1989","unstructured":"Blair GE, Dixon SC, Griffiths SA, Zajdel ME (1989) Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res 14:339\u2013346. https:\/\/doi.org\/10.1016\/0168-1702(89)90026-9","journal-title":"Virus Res"},{"key":"2774_CR45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-04-3046","volume":"65","author":"JM Ritz","year":"2005","unstructured":"Ritz JM, Kuhle O, Riethdorf S, Sipos B, Deppert W, Englert C, Gunes C (2005) A novel transgenic mouse model reveals humanlike regulation of an 8-kbp human TERT gene promoter fragment in normal and tumor tissues. Cancer Res 65:1187\u20131196. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3046","journal-title":"Cancer Res"},{"key":"2774_CR46","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1096\/fj.10-173989","volume":"25","author":"W Jia","year":"2011","unstructured":"Jia W, Wang S, Horner JW, Wang N, Wang H, Gunther EJ, DePinho RA, Zhu J (2011) A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J 25:979\u2013989. https:\/\/doi.org\/10.1096\/fj.10-173989","journal-title":"FASEB J"},{"key":"2774_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"G Schonrich","year":"2019","unstructured":"Schonrich G, Raftery MJ (2019) The PD-1\/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol 9:207. https:\/\/doi.org\/10.3389\/fcimb.2019.00207","journal-title":"Front Cell Infect Microbiol"},{"key":"2774_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","volume":"45","author":"M Muhlbauer","year":"2006","unstructured":"Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45:520\u2013528. https:\/\/doi.org\/10.1016\/j.jhep.2006.05.007","journal-title":"J Hepatol"},{"key":"2774_CR49","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1073\/pnas.0802095105","volume":"105","author":"KA Tworkowski","year":"2008","unstructured":"Tworkowski KA, Chakraborty AA, Samuelson AV, Seger YR, Narita M, Hannon GJ, Lowe SW, Tansey WP (2008) Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. Proc Natl Acad Sci USA 105:6103\u20136108. https:\/\/doi.org\/10.1073\/pnas.0802095105","journal-title":"Proc Natl Acad Sci USA"},{"key":"2774_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227\u2013231. https:\/\/doi.org\/10.1126\/science.aac9935","journal-title":"Science"},{"key":"2774_CR51","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48:434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","journal-title":"Immunity"},{"key":"2774_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, Smallwood CA, Siemens DR, Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74:665\u2013674. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0992","journal-title":"Cancer Res"},{"key":"2774_CR53","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.jbo.2019.100221","volume":"15","author":"P Thanindratarn","year":"2019","unstructured":"Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z (2019) Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol 15:100221. https:\/\/doi.org\/10.1016\/j.jbo.2019.100221","journal-title":"J Bone Oncol"},{"key":"2774_CR54","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416\u2013426. https:\/\/doi.org\/10.1016\/S1470-2045(18)30006-8","journal-title":"Lancet Oncol"},{"key":"2774_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R (2018) Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 6:46. https:\/\/doi.org\/10.1186\/s40425-018-0361-7","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02774-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T05:12:31Z","timestamp":1618636351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02774-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02774-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Urata is President & CEO of Oncolys BioPharma, Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma, Inc. The other authors disclosed no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}